Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Heart Failure Reports
Erschienen in: Current Heart Failure Reports 2/2018

21.02.2018 | Clinical Trials (J. Butler, Section Editor)

The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study

verfasst von: Nasrien E. Ibrahim, James L. Januzzi Jr

Erschienen in: Current Heart Failure Reports | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Biomarker-guided management of patients with chronic heart failure with reduced ejection fraction (HFrEF) remains controversial.

Recent Findings

Biomarkers have established roles for diagnosis and prognostication in HF. Pilot data suggested that use of natriuretic peptides might be helpful to guide HF care. The recent Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) randomized–controlled trial did not find therapy guided by NT-proBNP to be more effective than usual care in improving the primary endpoint of HF hospitalization or cardiovascular mortality amongst patients with chronic HFrEF. Patients in GUIDE-IT received similar care and had similar NT-proBNP lowering regardless of treatment allocation.

Summary

Though biomarkers retain important standing for diagnosis and prognosis in HF, the GUIDE-IT trial results suggest carefully managed patients may not benefit from a biomarker-guided strategy. Future studies focusing this intervention on patients treated in a more real-world setting are needed.
Literatur
1.
•• Yancy CW, Jessup M, Bozkurt B, et al. ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure. J Am Coll Cardiol. 2017;70:776–803. Most recent update to the heart failure guidelines. CrossRefPubMed
2.
•• Januzzi JL, Troughton R. Are serial BNP measurements useful in heart failure management?: Serial natriuretic peptide measurements are useful in heart failure management. Circulation. 2013;127:500–8. Informative debate on biomarker-guided management. CrossRefPubMed
3.
•• Desai AS. Are serial BNP measurements useful in heart failure management?: Serial natriuretic peptide measurements are not useful in heart failure management: the art of medicine remains long. Circulation. 2013;127:509–16. Informative debate on biomarker-guided management. CrossRefPubMed
4.
Fruhwald FM, Fahrleitner-Pammer A, Berger R, Leyva F, Freemantle N, Erdmann E, et al. Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. Eur Heart J. 2007;28:1592–7.CrossRefPubMed
5.
Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol. 2001;37:1228–33.CrossRefPubMed
6.
Frantz RP, Olson LJ, Grill D, Moualla SK, Nelson SM, Nobrega TP, et al. Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure. Am Heart J. 2005;149:541–7.CrossRefPubMed
7.
•• McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004. Landmark trial that brought neprilysin inhibition to the forefront of management of chronic systolic heart failure. CrossRefPubMed
8.
Januzzi JJL, Rehman SU, Mohammed AA, et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol. 2011;58:1881–9.CrossRefPubMed
9.
Troughton RW, Frampton CM, Brunner-La Rocca H-P, et al. Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur Heart J. 2014;35:1559–67.CrossRefPubMedPubMedCentral
10.
Weiner RB, Baggish AL, Chen-Tournoux A, Marshall JE, Gaggin HK, Bhardwaj A, et al. Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study. Eur J Heart Fail. 2013;15:342–51.CrossRefPubMed
11.
Gaggin HK, Truong QA, Rehman SU, Mohammed AA, Bhardwaj A, Parks KA, et al. Characterization and prediction of natriuretic peptide “nonresponse” during heart failure management: results from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) study. Congest Heart Fail. 2013;19:135–42.CrossRefPubMed
12.
Packer M, Poole-Wilson PA, Armstrong PW, Cleland JGF, Horowitz JD, Massie BM, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999;100:2312–8.CrossRefPubMed
13.
Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009;374:1840–8.CrossRefPubMed
14.
Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 1996;94:2807–16.CrossRefPubMed
15.
Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, et al. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the registry to improve the use of evidence-based heart failure therapies in the outpatient setting (IMPROVE HF). Circulation. 2010;122:585–96.CrossRefPubMed
16.
• Troughton RW, Frampton CM, Yandle TG, Espine EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126–30. Sentinel trial of biomarker-guided management. CrossRefPubMed
17.
Berger R, Moertl D, Peter S, Ahmadi R, Huelsmann M, Yamuti S, et al. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure: a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol. 2010;55:645–53.CrossRefPubMed
18.
Jourdain P, Jondeau G, Funck F, Gueffet P, le Helloco A, Donal E, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP multicenter study. J Am Coll Cardiol. 2007;49:1733–9.CrossRefPubMed
19.
Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG, et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-assisted treatment to lessen serial cardiac readmissions and death) trial. J Am Coll Cardiol. 2009;55:53–60.CrossRefPubMed
20.
Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, et al. BNP-guided vs symptom-guided heart failure therapy: the trial of intensified vs standard medical therapy in elderly patients with congestive heart failure (time-CHF) randomized trial. JAMA. 2009;301:383–92.CrossRefPubMed
21.
Eurlings LWM, van Pol PEJ, Kok WE, van Wijk S, Lodewijks-van der Bolt C, Balk AH, et al. Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol. 2010;56:2090–100.CrossRefPubMed
22.
Shah MR, Califf RM, Nohria A, Bhapkar M, Bowers M, Mancini DM, et al. The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure. J Card Fail. 2011;17:613–21.CrossRefPubMed
23.
Karlström P, Alehagen U, Boman K, Dahlström U, On behalf of the U-SG. Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome. Eur J Heart Fail. 2011;13:1096–103.CrossRefPubMed
24.
Pascual Figal D, Domingo M, Casas T, et al. Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients. Eur Heart J. 2008;29(8):1011–8.CrossRefPubMed
25.
Gandhi PU, Szymonifka J, Motiwala SR, Belcher AM, Januzzi JL Jr, Gaggin HK. Characterization and prediction of adverse events from intensive chronic heart failure management and effect on quality of life: results from the pro-B-type natriuretic peptide outpatient-tailored chronic heart failure therapy (PROTECT) study. J Card Fail. 2014;21:9–15.CrossRefPubMed
26.
Felker GM, Hasselblad V, Hernandez AF, O'Connor CM. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J. 2009;158:422–30.CrossRefPubMed
27.
Savarese G, Trimarco B, Dellegrottaglie S, Prastaro M, Gambardella F, Rengo G, et al. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials. PLoS One. 2013;8:e58287.CrossRefPubMedPubMedCentral
28.
•• Felker G, Anstrom KJ, Adams KF, et al. Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2017;318:713–20. The GUIDE-IT trial. CrossRefPubMedPubMedCentral
29.
•• Felker GM, Ahmad T, Anstrom KJ, et al. Rationale and Design of the GUIDing Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study. JACC Heart Fail. 2014;2:457–65. The design of the GUIDE-IT trial. CrossRefPubMedPubMedCentral
30.
Cleland JGF, McMurray JJV, Kjekshus J, Cornel JH, Dunselman P, Fonseca C, et al. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of Rosuvastatin: a report from CORONA (controlled Rosuvastatin multinational trial in heart failure). J Am Coll Cardiol. 2009;54:1850–9.CrossRefPubMed
31.
• Zile MR, Claggett BL, Prescott MF, et al. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. J Am Coll Cardiol. 2016;68:2425–36. Study that demonstrates better outcomes with NT-proBNP <1000 ng/mL. CrossRefPubMed
Metadaten
Titel
The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study
verfasst von
Nasrien E. Ibrahim
James L. Januzzi Jr
Publikationsdatum
21.02.2018
Verlag
Springer US
Erschienen in
Current Heart Failure Reports / Ausgabe 2/2018
Print ISSN: 1546-9530
Elektronische ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-018-0381-0

Weitere Artikel der Ausgabe 2/2018

Current Heart Failure Reports 2/2018 Zur Ausgabe

Clinical Trials (J. Butler, Section Editor)

Multiple Avenues of Modulating the Nitric Oxide Pathway in Heart Failure Clinical Trials

Pathophysiology of Myocardia Failure (I. Anand and M. Patarroyo Aponte A., Section Editors)

Right Ventricular Dysfunction and Its Contribution to Morbidity and Mortality in Left Ventricular Heart Failure

Nonpharmacologic Therapy: Surgery, Ventricular Assist Devices, Biventricular Pacing, and Exercise (A. Hasan, Section Editor)

The Evolving Role of Cardiorespiratory Fitness and Exercise in Prevention and Management of Heart Failure

Pathophysiology of Myocardia Failure (I. Anand and M. Patarroyo Aponte A., Section Editors)

Fill in the Gaps of Secondary Mitral Regurgitation: a Continuum Challenge From Pathophysiology to Prognosis

Pharmacologic Therapy (W.H.W. Tang, Section Editor)

Pulmonary Vascular Disease: Hemodynamic Assessment and Treatment Selection—Focus on Group II Pulmonary Hypertension

Clinical Trials (J. Butler, Section Editor)

Updates on Device-Based Therapies for Patients with Heart Failure

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise